Pharmaceutical

Immune-Onc’s antibody therapy collects second FDA orphan designation

The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.

Feb 22, 2024 - 18:00
Immune-Onc’s antibody therapy collects second FDA orphan designation
The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.
Read the original article

Tags:

Previous Article

Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 

Next Article

United Therapeutics sues FDA over handling of Liquidia’s NDA

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Telework helps FDA compete for scientists. What if it’s no longer an option?

STAT+: Telework helps FDA compete for scientists. What ...

May 11, 2023

Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs

Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs

Oct 12, 2023

QUT team receives US DoD funding for Parkinson’s treatment

QUT team receives US DoD funding for Parkinson’s treatment

May 29, 2024